

# Cristina Marinela Oprean

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/252/publications.pdf>

Version: 2024-02-01

19  
papers

574  
citations

1478505

6  
h-index

996975

15  
g-index

19  
all docs

19  
docs citations

19  
times ranked

787  
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis”The Adjuvant Role of Lifestyle Changes. <i>Current Oncology</i> , 2022, 29, 1890-1901.	2.2	1
2	Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4314.	2.6	5
3	Skin-Reducing Mastectomy and Immediate Reconstruction for a Large Recurrent Borderline Phyllodes Tumor. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 1224.	2.5	3
4	Unilateral Orbital Metastasis as the Unique Symptom in the Onset of Breast Cancer in a Postmenopausal Woman: Case Report and Review of the Literature. <i>Diagnostics</i> , 2021, 11, 725.	2.6	5
5	Comparative hematological profiles for dose”dense vs. regular anthracycline”based neoadjuvant chemotherapy in non”metastatic breast cancer. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 747.	1.8	0
6	Carcinomatous”like mastitis due to axillary lymphadenopathy in a case of nasopharyngeal carcinoma: A case report. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1026.	1.8	1
7	Well-Being, Depression, and Anxiety following Oncoplastic Breast Conserving Surgery versus Modified Radical Mastectomy Followed by Late Breast Reconstruction. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9320.	2.6	3
8	The Pattern of Second Primary Tumours in Postmenopausal Women with Prior Breast Cancer in Western Romania: A Retrospective, Single-Institution Study. <i>Diagnostics</i> , 2021, 11, 1957.	2.6	0
9	Postmenopausal Breast Cancer in Women, Clinical and Epidemiological Factors Related to the Molecular Subtype: A Retrospective Cohort Study in a Single Institution for 13 Years. Follow-Up Data. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8722.	2.6	2
10	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1269-1282.	10.7	207
11	The influence of cognitive schemas on the mixed anxiety-depressive symptoms of breast cancer patients. <i>BMC Women’s Health</i> , 2020, 20, 32.	2.0	10
12	Endurance of erythrocyte series in chemotherapy. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	1.8	2
13	Determining factors of renal dysfunction during cisplatin chemotherapy. <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 83.	1.8	3
14	Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 59-59.	1.6	5
15	NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. <i>Supportive Care in Cancer</i> , 2017, 25, 1127-1135.	2.2	37
16	Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). <i>Frontiers in Oncology</i> , 2016, 6, 232.	2.8	82
17	A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. <i>Annals of Oncology</i> , 2014, 25, 1328-1333.	1.2	202
18	No Evidence Of Increased Cyclophosphamide Toxicity Associated With The Antiemetic Agent NEPA, a Fixed-Dose Combination Of Netupitant and Palonosetron. <i>Blood</i> , 2013, 122, 2949-2949.	1.4	6

#	ARTICLE	IF	CITATIONS
19	P144 CELER: an international randomized phase III trial of the CESAR Group â€” or: Should chemotherapy be added to hormonal therapy in advanced breast cancer?. Breast, 2007, 16, S54.	2.2	0